Гіпертонічний розчин натрію хлориду – простий та ефективний засіб у лікуванні основних захворювань органів дихання
DOI:
https://doi.org/10.37987/1997-9894.2016.5-6(201-2).204726Ключові слова:
муковісцидоз, інші захворювання дихальної системи, гіпертонічний розчин натрію хлориду, гіалуронова кислотаАнотація
Захворювання органів дихання займають провідне місце в структурі загальної захворюваності населення України. Згідно з офіційними статистичними даними за період 2010–2014 рр. захворювання органів дихання займали друге місце у структурі поширеності хвороб серед дорослого населення, а в структурі захворюваності – перше. Перед сучасною медициною постійно постає питання підбору ефективної терапії основних патогенетичних ланок захворювань бронхолегеневої системи. В статті наведено дані міжнародних досліджень з вивчення ефективності гіпертонічного розчину натрію хлориду при лікуванні деяких захворювань органів дихання. Було виявлено переконливі дані його високої ефективності.
Посилання
Aitken M.L. Analysis of sequential aliquots of hypertonic saline solution-induced sputum from clinically stable patients with cystic fibrosis / M.L. Aitken, K.E. Greene, M.R. Tonelli et al. // Chest. – 2003. – Vol. 123, № 3. – Р. 792–799.
Al-Ansari K. Nebulized 5% or 3% hypertonic or 0.9% saline for treating acute bronchiolitis in infants / K. Al-Ansari, M. Sakran, B.L. Davidson, R. El Sayyed, H. Mahjoub, K. Ibrahim // Journal of Pediatrics. – 2010. – Vol. 157, №4. – Р. 630– 634.
Amin R. Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function / R. Amin, P. Subbarao, A. Jabar et al. // Thorax. – 2010. – Vol. 65, № 5. – Р. 379–383.
Ballmann M. Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis / M. Ballmann and H. Von Der Hardt // Journal of Cystic Fibrosis. – 2002. – Vol. 1, №1. – Р. 35–37.
Barańska-Rybak W. Glycosaminoglycans inhibit the antibacterial activity of LL-37 in biological fluids / W. Barańska-Rybak, A. Sonesson, R. Nowicki, A. Schmidtchen // Journal of Antimicrobial Chemotherapy. – 2006. – Vol. 57, № 2. – Р. 260–265.
Bathoorn E. Van Oosterhout, Kerstjens H.A.M. Safety of sputum induction during exacerbations of COPD / E. Bathoorn, J. Liesker, D. Postma, G. Koëter, A.J.M. Van Oosterhout, H.A.M. Kerstjens // Chest. – 2007. – Vol. 131, №2. – Р. 432–438.
Bergsson G. LL-37 complexation with glycosaminoglycans in cystic fibrosis lungs inhibits antimicrobial activity, which can be restored by hypertonic saline / G. Bergsson, E.P. Reeves, P. McNally et al. // Journal of Immunology. – 2009. – Vol. 183, №1. – Р. 543–551.
Boucher R.C. Evidence for airway surface dehydration as the initiating event in CF airway disease / R. C. Boucher // Journal of Internal Medicine. – 2007. – Vol. 261, №1. – Р. 5–16.
Buonpensiero P. Hyaluronic acid improves «pleasantness» and tolerability of nebulized hypertonic saline in a cohort of patients with cystic fibrosis / Buonpensiero P., De Gregorio F., Sepe A. et al. // Adv. Ther. – 2010. – Vol. 27. – P. 870–878.
Buonpensiero P. Hyaluronic acid improves «pleasantness» and tolerability of nebulized hypertonic saline in a cohort of patients with cystic fibrosis / P. Buonpensiero, F. De Gregorio, A. Sepe et al. // Advances in Therapy. – 2010. – Vol. 27, №11. – Р. 870–878.
Carpagnano G.E. Use of exhaled breath condensate in the study of airway inflammation after hypertonic saline solution challenge / G.E. Carpagnano, M.P.F. Barbaro, M. Cagnazzo et al. // Chest. – 2005. – Vol. 128, №5. – Р. 3159–3166.
Clunes M.T. Front-runners for pharmacotherapeutic correction of the airway ion transport defect in cystic fibrosis / M.T. Clunes, R.C. Boucher // Current Opinion in Pharmacology. – 2008. – Vol. 8, №3. – Р. 292–299.
Dellon E.P. Safety and tolerability of inhaled hypertonic saline in young children with cystic fibrosis / E.P. Dellon, S.H. Donaldson, R. Johnson, S.D. Davis // Pediatric Pulmonology. – 2008. – Vol. 43, №11. – Р. 1100–1106.
Donaldson S.H. Mucus clearance and lung function in cystic fibrosis with hypertonic saline / S.H. Donaldson, W.D. Bennett, K.L. Zeman, M.R. Knowles, R. Tarran, R.C. Boucher // New England Journal of Medicine. – 2006. – Vol. 354, №3. Р. 241–250.
Elkins M.R. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis / M.R. Elkins, M. Robinson, B.R. Rose et al. // New England Journal of Medicine. – 2006. – Vol. 354, №3. – Р. 229–240.
Enderby B. Hypertonic saline inhalation in cystic fibrosis–salt in the wound, or sweet success? / B. Enderby, I. Doull // Archives of Disease in Childhood. – 2007. – Vol. 92, №3. – Р. 195–196.
Eng P.A. Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis / P.A. Eng, J. Morton, J.A. Douglass, J. Riedler, J. Wilson, C.F. Robertson // Pediatric Pulmonology. – 1996. – Vol. 21, №2. – Р. 77–83.
Fahy J.V. Safety and reproducibility of sputum induction in asthmatic subjects in a multicenter study / J.V. Fahy, H.A. Boushey, S.C. Lazarus et al. // American Journal of Respiratory and Critical Care Medicine. – 2001. – Vol. 163, №6. – Р. 1470–1475.
Fuchs H.J. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis / H.J. Fuchs, D.S. Borowitz, D.H. Christiansen et al. // New England Journal of Medicine. – 1994. – Vol. 331, №10. – Р. 637–642.
Furnari M.L. Nebulized hypertonic saline containing hyaluronic acid improves tolerability in patients with cystic fibrosis and lung disease compared with nebulized hypertonic saline alone: a prospective, randomized, doubleblind, controlled study / Furnari M.L., Termini L., Traverso G. et al. // Therap Adv. Respir. Dis. – 2012. – Vol. 6. – Р. 315–322.
Gould N.S. Hypertonic saline increases lung epithelial lining fluid glutathione and thiocyanate: two protective CFTR-dependent thiols against oxidative injury / N.S. Gould, S. Gauthier, C.T. Kariya, E. Min, J. Huang, B.J. Day // Respiratory Research. – 2010. – Vol. 11, art. 119.
Hashimoto S. Hyperosmolarity-induced interleukin-8 expression in human bronchial epithelial ceils through p38 mitogen-activated protein kinase / S. Hashimoto, K. Matsumoto, Y. Gon, T. Nakayama, I. Takeshita, T. Horie // American Journal of Respiratory and Critical Care Medicine. – 1999. – Vol. 159, №2. – Р. 634–640.
Hassett D.J. Pseudomonas aeruginosa biofilm infections in cystic fibrosis: insights into pathogenic processes and treatment strategies / D.J. Hassett, T.R. Korfhagen, R.T. Irvin et al. // Expert Opinion on Therapeutic Targets. – 2010. – Vol. 14, №2. – Р. 117–130.
Havasi V. Inhibitory effects of hypertonic saline on P. aeruginosa motility / V. Havasi, C.O. Hurst, T.C. Briles et al. // Journal of Cystic Fibrosis. – 2008. – Vol. 7, №4. – Р. 267–269.
Hebestreit A. Hypertonic saline inhibits luminal sodium channels in respiratory epithelium / A. Hebestreit, U. Kersting, H. Hebestreit // European Journal of Applied Physiology. – 2007. – Vol. 100, №2. – Р. 177–183.
Hubbard R.C. A preliminary study of aerosolized recombinant human deoxyribonuclease I in the treatment of cystic fibrosis / R.C. Hubbard, N.G. McElvaney, P. Birrer et al. // New England Journal of Medicine. – 1992. – Vol. 326, №12. – Р. 812–815.
Jones A.P. Dornase alfa for cystic fibrosis / A.P. Jones, C. Wallis // Cochrane Database of Systematic Reviews. – 2010. – Vol. 3. – Р. CD001127.
Kahl B.C. Impact of Staphylococcus aureus on the pathogenesis of chronic cystic fibrosis lung disease / B.C. Kahl // International Journal of Medical Microbiology. – 2010. – Vol. 300, №8. – Р. 514–519.
Kaneider N.C. Heparan sulfate proteoglycan-involving immunomodulation by cathelicidin antimicrobial peptides LL-37 and PR-39 / N.C. Kaneider, A. Djanani, C.J. Wiedermann // The Scientific World Journal. – 2007. – Vol. 7. – Р. 1832–1838.
Kellett F. Evaluation of nebulised hypertonic saline (7%) as an adjunct to physiotherapy in patients with stable bronchiectasis / F. Kellett, J. Redfern, R. McL Niven // Respiratory Medicine. – 2005. – Vol. 99, №1. – Р. 27–31.
Kellett F. Nebulised 7% hypertonic saline improves lung function and quality of life in bronchiectasis / F. Kellett, N.M. Robert // Respiratory Medicine. – 2011. – Vol. 105, №12. – Р. 1831–1835.
King M. Rheology of cystic fibrosis sputum after in vitro treatment with hypertonic saline alone and in combination with recombinant human deoxyribonuclease I / M. King, B. Dasgupta, R.P. Tomkiewicz, N.E. Brown // American Journal of Respiratory and Critical Care Medicine. – 1997. – Vol. 156, №1. – Р. 173–177.
Lee L. Hypertonic saline inhibits arachidonic acid priming of the human neutrophil / L. Lee, M.R. Kelher, E.E. Moore, A. Banerjee, C.C. Silliman // Journal of Surgical Research. – 2012. – Vol. 174, №1. – Р. 24–28.
Matsui H. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways diseas e/ H. Matsui, B.R. Grubb, R. Tarran et al. // Cell. – 1998. – Vol. 95, №7. – Р. 1005–1015.
Nash E.F. Nebulized and oral thiol derivatives for pulmonary disease in cystic fibrosis / E.F. Nash, A. Stephenson, F. Ratjen, E. Tullis // Cochrane Database of Systematic Reviews. – 2009. – №1. – Р. CD007168.
O’Sullivan B.P. The clinical approach to lung disease in patients with cystic fibrosis / B.P. O’Sullivan, P. Flume // Seminars in Respiratory and Critical Care Medicine. – 2009. –Vol. 30, №5. –Р. 505–513.
Ramsey B.W. Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis / B.W. Ramsey, S.J. Astley, M.L. Aitken et al. // American Review of Respiratory Disease. – 1993. – Vol. 148, №1. – Р. 145–151.
Ranasinha C. Efficacy and safety of short-term administration of aerosolised recombinant human DNase I in adults with stable stage cystic fibrosis / C. Ranasinha, B. Assoufi, S. Shak et al. // The Lancet. – 1993. – Vol. 342, №8865. – Р. 199–202.
Rand Sutherland E. Sputum induction in COPD–it’s safe, so now what do we do? / E. Rand Sutherland // Journal of Chronic Obstructive Pulmonary Disease. – 2006. – Vol. 3, №2. – Р. 73–74.
Reeves E.P. Nebulized hypertonic saline decreases IL-8 in sputum of patients with cystic fibrosis / E.P. Reeves, M. Williamson, S.J. O’Neill, P. Greally, N.G. McElvaney // American Journal of Respiratory and Critical Care Medicine. – 2011. – Vol. 183, №11. – Р. 1517–1523
Robinson M. Effect of hypertonic saline, amiloride, and cough on mucociliary clearance in patients with cystic fibrosis / M. Robinson, J.A. Regnis, D.L. Bailey, M. King, G.J. Bautovich, P.T.P. Bye // American Journal of Respiratory and Critical Care Medicine. – 1996. – Vol. 153, №5. – Р. 1503–1509.
Ros M. Hyaluronic acid improves the tolerability of hypertonic saline in the chronic treatment of cystic fibrosis patients: a multicenter, randomized, controlled clinical trial / Ros M., Casciaro R., Lucca F. et al. // J. Aerosol. Med. Pulm. Drug Deliv. – 2014. – Vol. 27. – Р. 133–137.
Rosenfeld M. Inhaled hypertonic saline in infants and toddlers with cystic fibrosis: short-term tolerability, adherence, and safety / Rosenfeld M., Davis S., Brumback L. et al. // Pediatr. Pulmonol. – 2011. – Vol. 46. –Р. 666–671.
Schaeffer V. Role of the mTOR pathway in LPS-activated monocytes: influence of hypertonic saline / V. Schaeffer, S. Arbabi, I.A. Garcia et al. // Journal of Surgical Research. – 2010. – Vol. 171, №2. – Р. 769–776.
Shak S. Recombinant human DNase Ireducesthe viscosity of cystic fibrosissputum/ S. Shak, D.J. Capon, R. Hellmiss, S.A. Marsters, C.L. Baker // Proceedings of theNationalAcademy of Sciences of theUnited States ofAmerica.–1990.–Vol. 87,№23.–Р. 9188–9192.
Suri R. A comparative study of hypertonic saline, daily and alternate-day rhDNase in children with cystic fibrosis / R. Suri, C. Wallis, A. Bush et al. // Health Technology Assessment. – 2002. – Vol. 6, №34. – Р. 1–60.
Suri R. Comparison of hypertonic saline and alternate-day or daily recombinant human deoxyribonuclease in children with cystic fibrosis: a randomised trial / R. Suri, C. Metcalfe, B.Lees et al. // The Lancet. – 2001. – Vol. 358,№9290. – Р. 1316–1321.
Suri R. Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis / R. Suri, L.J. Marshall, C. Wallis, C. Metcalfe, A. Bush, J.K. Shute // American Journal of Respiratory and Critical Care Medicine. – 2002. – Vol. 166, №3. – Р. 352–355.
Tarran R. Rationale for hypertonic saline therapy for cystic fibrosis lung disease / Tarran R., Donaldson S., Boucher R.C. // Semin. Respir. Crit. Care Med. – 2007. – Vol. 28. –Р. 295–302.
Tarran R. Normal and cystic fibrosis airway surface liquid homeostasis: the effects of phasic shear stress and viral infections / R. Tarran, B. Button, M. Picher et al. // Journal of Biological Chemistry. – 2005. – Vol. 280, №42. – Р. 35751–35759.
Tarran R. The CF salt controversy: in vivo observations and therapeutic approaches / R. Tarran, B.R. Grubb, D. Parsons et al. // Molecular Cell. – 2001. – Vol. 8, №1. – Р. 149–158.
Toungoussova O. Changes in sputum composition during 15 min of sputum induction in healthy subjects and patients with asthma and chronic obstructive pulmonary disease / O. Toungoussova, G.B. Migliori, M.P. Foschino Barbaro et al. // Respiratory Medicine. – 2007. – Vol. 101, №7. – Р. 1543–1548.
Voynow J.A. Proteases and cystic fibrosis / Voynow J.A., Fischer B.M., Zheng S. // Int. J. Biochem. Cell Biol. – 2008. – Vol. 40. – Р. 1238–1245.
Wark P. Nebulised hypertonic saline for cystic fibrosis / P. Wark, V.M. McDonald // Cochrane Database of Systematic Reviews. – 2009. – №2. – Р. CD001506.
Wilson A.M. Safety of sputum induction in moderate-to-severe smoking-related chronic obstructive pulmonary disease / A.M. Wilson, R. Leigh, F.E. Hargreave, M.M.M. Pizzichini, E. Pizzichini // Journal of Chronic Obstructive Pulmonary Disease. – 2006. – Vol. 3, №2. – Р. 89–93.
Wood R.E. Cystic fibrosis / R.E. Wood, T.F. Boat, C.F. Doershuk // American Review of Respiratory Disease. – 1976. – Vol. 113, №6. – Р. 833–878.
Xiao W. Sputum cathelicidin, urokinase plasminogen activation system components, and cytokines discriminate cystic fibrosis, COPD, and asthma inflammation / W. Xiao, Y.P. Hsu, A. Ishizaka, T. Kirikae, R.B. Moss // Chest. – 2005. – Vol. 128, №4. – Р. 2316–2326.
Zhang L. Nebulised hypertonic saline solution for acute bronchiolitisin infants(Review) / Zhang L., Mendoza-Sassi R.A., Wainwright C., Klassen T.P. // The Cochrane Library. – 2013. – Issue 7. – Режим доступу: http://www.thecochranelibrary.com.
Режим доступу: http://commons.pacificu.edu/pa/463.
Режим доступу: http://www.dec.gov.ua.
